Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Combogesic IV
- Development stage
- Approved
- Lead developer
- AFT Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Combogesic IV is an intravenous fixed-dose combination analgesic containing acetaminophen (1000 mg) and ibuprofen (300 mg). Developed by AFT Pharmaceuticals and distributed in the United States by Hikma Pharmaceuticals, it is indicated for the management of mild-to-moderate pain and as an adjunct to opioid analgesics for moderate-to-severe pain in adults. Acetaminophen provides analgesia through central mechanisms, while ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis. The product received FDA approval in October 2023 and is marketed internationally under the brand name Maxigesic IV. It is currently undergoing Phase 3 clinical evaluation for use in pediatric populations.
- Brand names
- Combogesic IVMaxigesic IV
- Other names
- acetaminophen + ibuprofen intravenous
02
Targets
CNR1 (Cannabinoid receptor 1)FAAHPGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Combogesic IV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Combogesic IV.